Sunhawk Vision Biotech - Kaohsiung

Sunhawk Vision Biotech, founded by Prof. Suh-Hang Juo from China Medical University, Taiwan, is leveraging the myopia epidemic in Asia – where over 85% of the population has shortsightedness – as a business opportunity. Our core technology involves the use of a novel anti-sense oligonucleotide contained in eye drops, which has been proven to effectively neutralize specific over-expressed microRNA that influences myopia development. After discussing with the FDA, the underlying regulatory pathway has been identified and efforts are underway to complete animal toxicology tests by 2020 to assist with the Investigational New Drug (IND) application in 2020-2021. SHJ002 offers numerous benefits, including: 1. Greater effectiveness and fewer side effects than atropine eye drops. 2. No risks  

Show more

associated with laser eye surgery, enabling individuals to avoid the inconvenience of wearing glasses. 3. Reduced progression of myopia and prevention of short sightedness complications. 4. No toxicities observed in animal toxicology tests.